Trial will evaluate the effect of this combination therapy on minimal residual disease Memorial Sloan Kettering Cancer Center Now Enrolling Patients in Phase 1/2 Clinical Trial of IMUNON’s IMNN-001 in Combination with Bevacizumab in Advanced Ovarian Cancer
Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types Myriad’s Precise MRD test will be used to evaluate the broad applicability of MRD testing across many cancer types Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial,…
CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB). MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor
QIAGEN Biomedical KB-AI enthält mehr als 640 Millionen biomedizinische Beziehungen, darunter Kausalzusammenhänge zwischen Genen, Krankheiten und Medikamenten, zur Beschleunigung der datenbasierten Arzneimittelforschung // Ergänzt von Menschen kuratierte QIAGEN Biomedical KB-HD und hilft bei der Identifizierung neuer Zusammenhänge zwischen Krankheiten, biologischen Signalwegen und molekularen Wechselwirkungen, die mit herkömmlichen Methoden übersehen werden können // Workflow verkürzt die Hypothesenprüfung…
Highlights: Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance
HOLLISTON, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2023 before the market opens on March 7, 2024, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time. Harvard Bioscience Schedules Fourth Quarter 2023 Earnings…
QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven drug discovery // AI-driven insights complement human-curated QIAGEN Biomedical KB-HD and help identify novel relationships between diseases, biological pathways and molecular interactions that may be missed by traditional methods // Workflow cuts down on hypothesis…
Blockchain’s inherent transparency, while beneficial for validation and trust, poses significant privacy concerns. Traditional transactions on public blockchains are permanently visible, compromising user privacy. This visibility has been a double-edged sword, providing transparency but at the cost of personal data exposure. A new protocol called Privacy Pools offers a potential solution to the seemingly contradictory…
Une équipe de chercheurs de l’Université de Bath a mis au point un nouvel outil pour le développement de nouveaux traitements pharmaceutiques de manière plus écologique et moins coûteuse. Leur innovation repose sur l’utilisation de protéines cycliques, une approche alternative aux molécules conventionnelles, dans la fabrication de médicaments. Traditionnellement, les traitements médicamenteux interagissent avec des…
SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) — ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced positive efficacy results in its phase 2 inpatient chronic spontaneous urticaria study with neffy (epinephrine nasal spray),…
